Market News & Trends
Avectas, CCRM & OmniaBio Expand Their Collaboration to Accelerate the Manufacture of Edited iPSCs Using SOLUPORE Technology
Avectas and CCRM, with its subsidiary OmniaBio Inc., have recently announced an expansion of their collaboration, to enable the development of gene-edited induced pluripotent stem….
Immutep Enters Second Clinical Trial Collaboration Agreement With Merck KGaA & Pfizer for New Combination Study of its First-in-Class LAG-3 Candidate, Eftilagimod Alpha & Avelumab to Treat Urothelial Cancer
New collaboration builds on encouraging clinical data previously reported from INSIGHT-004 in multiple solid tumor indications from the combination of eftilagimod alpha (efti) and avelumab (BAVENCIO)….
Context Therapeutics Nominates CTIM-76 Bispecific Antibody Candidate to Develop Treatment for Claudin 6-Positive Solid Tumors
Context Therapeutics Inc. recently announced the selection of CTIM-76, a T cell-engaging bispecific antibody, as its lead clinical development candidate to target Claudin 6 (CLDN6)…
INmune Bio Focused on Novel Clinical Trial Designs to Advance Next Generation of Alzheimer’s Disease Treatments
INmune Bio, Inc. recently participated in the 15th CTAD Conference in San Francisco November 29 to December 2. “This year’s CTAD is showcasing a potential…
Incannex Engages Eurofins to Manufacture Novel Addiction Treatments CannQuit-N and CannQuit-O
Incannex Healthcare Limited recently announced it has engaged multinational contract development and manufacturing organisation (CDMO) Eurofins Scientific to manufacture Incannex’s two distinct medicated….
Enlivex Receives Allocetra IND Clearance From the US FDA for Treatment of Patients With Advanced Solid Malignancies
Enlivex Therapeutics Ltd. recently announced the US FDA has cleared an Investigational New Drug (IND) application to study Allocetra in patients with advanced solid malignancies.…
Lantheus Announces the Approval of Perflutren Lipid Microsphere by China’s NMPA
Lantheus Holdings, Inc. recently announced the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has approved the Import Drug License (IDL)…
uniQure Announces FDA Approval of First Gene Therapy for Adults With Hemophilia B
Historic approval provides a new treatment option that reduces the rate of annual bleeds, reduces or eliminates the need for prophylactic therapy, and generates elevated and sustained factor IX levels….
XOMA Acquires Royalty & Milestone License to Ebopiprant, a Preterm Labor Asset, Being Developed by Organon
XOMA assumes the rights to ebopiprant from ObsEva, including the Organon License, Patent Estate, and Merck KGaA, Darmstadt, Germany, license, for a $15 million outlay….
IntelGenx Receives FDA PDUFA Date for RIZAFILM
IntelGenx Corp., a leader in pharmaceutical films, recently announced the US FDA has accepted for review its Class 2 response to the 2020 Complete Response…
Palisade Bio is Granted Fast Track Designation From US FDA for LB1148 for Accelerated Return of Bowel Function following GI Surgery
Palisade Bio, Inc. recently announced the US FDA has granted Fast Track designation to LB1148 for the acceleration of time to return of bowel function…
RxCelerate Acquires Methuselah Health & Launches ProQuant World-Beating Proteomics Service
Next-generation proteomics technology made available to the biotech and pharmaceutical industry through the acquisition of Methuselah Health by leading R&D services provider, RxCelerate….
Evaxion Announces Promising Results From Phase 1/2a Clinical Trial of Personalized DNA Cancer Immunotherapy
Evaxion Biotech A/S recently announced promising clinical data from the Phase 1/2a first-in-human study of its DNA-based cancer immunotherapy, EVX-02….
Attralus & Ossianix Announce Option & License Agreement Using the TXP1 Brain Shuttle for Targeted Delivery of a Pan-Amyloid Removal Therapeutic for Neurodegenerative Disorders
Attralus, Inc. and Ossianix recently announced they have entered into a definitive agreement using Ossianix’ brain shuttle technology to enhance the targeted delivery of novel….
VYNE Therapeutics Announces First Subjects Dosed in Phase 1a/b Clinical Trial Evaluating Pan-BET Inhibitor for the Treatment of Vitiligo
VYNE Therapeutics Inc. recently announced the first subjects have been dosed in a Phase 1a/b clinical trial evaluating VYN201 for the treatment of vitiligo. VYN201…
Editas Medicine Announces Clinical Data Demonstrating Proof of Concept of EDIT-101 From Phase 1/2 BRILLIANCE Trial
Editas Medicine, Inc. recently announced clinical data from the Phase 1/2 BRILLIANCE trial of EDIT-101, an in vivo CRISPR/Cas9 genome editing medicine in a company-sponsored…
Meridian Medical Technologies & Kindeva Drug Delivery to Combine
Meridian Medical Technologies recently announced it will combine with Kindeva Drug Delivery to create a leading global drug-device combination product Contract Development and….
Kinarus Therapeutics Engages Great Health Companion Group to Explore Partnerships in China
Kinarus to explore partnerships in China to fund Phase 2 clinical trials of KIN001 and explore further business opportunities….
Monopar Announces Encouraging Clinical Data From Ongoing Camsirubicin Phase 1b Trial
Monopar Therapeutics Inc. recently released encouraging data from its ongoing Phase 1b open-label clinical trial of camsirubicin in advanced soft tissue sarcoma patients. The data…
Key Patent Issued on Eligo’s Gene-Editing Breakthroughs Applied to Skin Disorders
Eligo Bioscience recently announced the issuance by the USPTO of the first patent in a wide family covering genetic engineering of a key skin microbiome species, Cutibacterium acnes, to support….
